Carolyn Chew is an avid public healthcare advocate with over 10+ years of cross-healthcare stakeholder experience. She is looking to partner with innovative progressive employers who would like to join in the movement with GRAIL to detect cancer early! Carolyn’s experience has been to bring innovative products to market. She has spent her earlier years in academic pre-clinical research identifying if diet plays a key role in delaying early onset to dementia, a precursor to Alzheimer’s, and was part of the VA/UCLA Alzheimer’s Research medical team that have published an article on the effects of Curcumin on Alzheimer’s disease. She later consulted with life science companies for 5 years at PricewaterhouseCoopers with leading pharma and healthcare provider companies applying channel strategy and patient centricity tactics to optimize the value of therapeutics in the healthcare marketplace. Carolyn has been recognized as standing author to the one of the notable PwC White Papers “Behind the Numbers” evaluating the cost trends of the payer world and what leads to its evolution. Just before joining GRAIL, Carolyn spent 7 years at Genentech in marketing and market access where the has brought products with the highest unmet need to the market often designated with FDA breakthrough designation and/or priority status review, such as Hemlibra, Cotellic/Zelboraf, and Lucentis. Carolyn holds a BS in Neuroscience / Chinese (Bates College) and Masters in Public Health in Health Service Management (UCLA).